New FDA regulatory initiatives improving rare disease drug development
This audiogram is part of The Regulatory Navigator series, where we explore the evolving regulatory landscape with actionable insight from Parexel's experts, sharing their experience to maximize success for clinical development and patient access.
Listen to Parexel's SVP of Global Regulatory Strategy Mwango Kashoki, M.D., M.P.H., who is also a former FDA regulator, on how the FDA's new "plausible mechanism pathway" aims to advance individualized therapies like gene editing for serious rare diseases with no adequate treatments.
Building on recent CRISPR approvals and Rare Disease Evidence Principles, this promising development for drug innovation has the healthcare community eagerly awaiting further details to fully realize its potential for patients with very rare genetic conditions.
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
FDA Rare Disease Innovation Hub: Enhancing Collaboration and Speed?
Jan 7, 2025
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Related Insights
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
FDA Rare Disease Innovation Hub: Enhancing Collaboration and Speed?
Jan 7, 2025
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025